PP
RCKT icon

PDT Partners’s Rocket Pharmaceuticals RCKT Stock Holding History

PDT Partners’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$638K Hold
186,596
– – 0.03% 372
2026
Q1 		$668K Sell
186,596
-34,288
-16% -$136K 0.04% 386
2025
Q4 		$775K Sell
220,884
-45,098
-17% -$154K 0.05% 369
2025
Q3 		$867K Hold
265,982
– – 0.05% 376
2025
Q2 		$652K Buy
+265,982
New +$1.35M 0.04% 489
2022
Q4 		– Sell
-90,217
Closed -$1.44M – 845
2022
Q3 		$1.44M Sell
90,217
-22,512
-20% -$351K 0.22% 133
2022
Q2 		$1.55M Buy
112,729
+48,505
+76% +$578K 0.14% 239
2022
Q1 		$1.02M Buy
+64,224
New +$1.11M 0.09% 365

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

PDT Partners's RCKT Position: Q2 2026 in Review

PDT Partners held its Rocket Pharmaceuticals (RCKT) position steady in Q2 2026 at 186,596 shares worth $638K. The position accounts for 0.03% of the portfolio, ranked #372.

PDT Partners first reported a position in RCKT in Q1 2022 and has held it in 8 quarters since. The position peaked at $1.55M in Q2 2022. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • PDT Partners held 186,596 shares of Rocket Pharmaceuticals worth $638K as of Q2 2026.
  • PDT Partners left its Rocket Pharmaceuticals share count unchanged in Q2 2026.
  • Rocket Pharmaceuticals made up 0.03% of PDT Partners's portfolio in Q2 2026, its #372 holding.
  • PDT Partners first reported a position in Rocket Pharmaceuticals in Q1 2022 and has held it in 8 quarters since.
  • PDT Partners's Rocket Pharmaceuticals position peaked at $1.55M in Q2 2022.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on PDT Partners's 13F filing for Q2 2026, filed 14 Aug 2026.